Our data linking OL differentiation with NOX3 and NOX5 expression and activity, suggest that NOX enzymes can represent potential targets of new regenerative therapies ending and reversing the progression of the lesions in MS. This evidence concerns the gene NOX3 and myeloid sarcoma.